<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03932786</url>
  </required_header>
  <id_info>
    <org_study_id>VICC PED 1878</org_study_id>
    <secondary_id>NCI-2019-00635</secondary_id>
    <secondary_id>1R01CA225005-01A1</secondary_id>
    <nct_id>NCT03932786</nct_id>
  </id_info>
  <brief_title>Studying Health Outcomes After Treatment in Patients With Retinoblastoma</brief_title>
  <acronym>RIVERBOAT</acronym>
  <official_title>Research Into Visual Endpoints and RB Health Outcomes After Treatment (RIVERBOAT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt-Ingram Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt-Ingram Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial studies health outcomes after treatment in patients with retinoblastoma. Gathering&#xD;
      health information over time from patients and family members through vision assessments,&#xD;
      samples of tissue and saliva, and questionnaires may help doctors learn more about what&#xD;
      causes retinoblastoma, identify long-term health outcomes for patients with retinoblastoma,&#xD;
      and find out which therapies may be the best for treating retinoblastoma&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Define acute toxicity, subsequent malignant neoplasm (SMN) risk and visual outcomes in&#xD;
      retinoblastoma (RB) survivors and compare patient centered psychosocial and neurocognitive&#xD;
      and physical outcomes in survivors with normative data and sibling controls.&#xD;
&#xD;
      II. Create the first Clinically-Annotated Patient Tissues to Analyze Gene INteractions to&#xD;
      assess biologic correlates of disease and facilitate future research: The RIVERBOAT-CAPTAIN&#xD;
      biorepository, including germline deoxyribonucleic acid (DNA) and tumor tissue from patients,&#xD;
      with detailed patient, disease and treatment-related information.&#xD;
&#xD;
      III. Using the RIVERBOAT-CAPTAIN clinically-annotated biorepository, determine the interplay&#xD;
      between specific RB1 mutation type and the role of additional modifier genes in determining&#xD;
      those tumor phenotypes that drive treatment decisions.&#xD;
&#xD;
      OUTLINE: Patients are assigned to 1 of 2 cohorts.&#xD;
&#xD;
      RETROSPECTIVE COHORT: Patients treated between 2008-2018 undergo collection of saliva samples&#xD;
      at &gt;= 6 months after treatment, and undergo vision assessment at &gt;= 6 months after treatment&#xD;
      and again 1 year later if necessary. Previously collected tissue samples at the time of&#xD;
      surgery are also obtained. Patients also complete questionnaires at &gt;= 6 months after&#xD;
      treatment and again 2 years later.&#xD;
&#xD;
      PROSPECTIVE COHORT: Patients treated between 2018-2023 undergo collection of saliva samples&#xD;
      at the time of enrollment and at 6 months after treatment. Patients also undergo vision&#xD;
      assessment at the time of enrollment, at 6 months, and 18 months after completion of&#xD;
      treatment. Patients also complete questionnaires at 6 months and again 2 years later, as well&#xD;
      as undergo collection of tissue samples at the time of surgery. Immediate family members with&#xD;
      history of RB or RB1 gene mutation also undergo collection saliva samples.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 24, 2019</start_date>
  <completion_date type="Anticipated">January 2026</completion_date>
  <primary_completion_date type="Anticipated">January 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of acute toxicity</measure>
    <time_frame>Up to 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Estimate malignant neoplasm (SMN) risk .Measured through medical record abstraction,</measure>
    <time_frame>Up to 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess visual outcomes measured via age appropriate visual acuity testing</measure>
    <time_frame>Up to 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess psycho-social outcomes utilizing questionnaires: BRIEF</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Genes will be tested to examine the role they play in Retinoblastoma. This will be done via whole-exome sequencing and whole RB1 Gene examination.</measure>
    <time_frame>Up to 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess quality of life utilizing questionnaires: BRIEF</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess quality of life utilizing questionnaires: CBCL</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess quality of life utilizing questionnaires: Youth Self-Report</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess quality of life utilizing questionnaires: Pediatric Quality of Life</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess visual outcomes measured via parent report</measure>
    <time_frame>Up to 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess visual outcomes measured via vision questionnaires</measure>
    <time_frame>Up to 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess psycho-social outcomes utilizing questionnaires: BRIEF-P,</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess psycho-social outcomes utilizing questionnaires: CBCL</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess psycho-social outcomes utilizing questionnaires: Youth Self-Report</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess psycho-social outcomes utilizing questionnaires: Pediatric Quality of Life</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">900</enrollment>
  <condition>Retinoblastoma</condition>
  <condition>Cancer Survivor</condition>
  <condition>Biological Sibling</condition>
  <condition>Intraocular Retinoblastoma</condition>
  <condition>Unilateral Retinoblastoma</condition>
  <arm_group>
    <arm_group_label>Retrospective(biospecimens, vision assessment, questionnaires)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Prospective (biospecimens, vision assessment, questionnaires)</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biospecimen collection</intervention_name>
    <description>Collection of tissue and saliva samples</description>
    <arm_group_label>Prospective (biospecimens, vision assessment, questionnaires)</arm_group_label>
    <arm_group_label>Retrospective(biospecimens, vision assessment, questionnaires)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vision assessment</intervention_name>
    <description>Undergo vision assessment</description>
    <arm_group_label>Prospective (biospecimens, vision assessment, questionnaires)</arm_group_label>
    <arm_group_label>Retrospective(biospecimens, vision assessment, questionnaires)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire administration</intervention_name>
    <description>Complete questionnaires</description>
    <arm_group_label>Prospective (biospecimens, vision assessment, questionnaires)</arm_group_label>
    <arm_group_label>Retrospective(biospecimens, vision assessment, questionnaires)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality of life assessment</intervention_name>
    <description>Complete questionnaires</description>
    <arm_group_label>Prospective (biospecimens, vision assessment, questionnaires)</arm_group_label>
    <arm_group_label>Retrospective(biospecimens, vision assessment, questionnaires)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Prospective (biospecimens, vision assessment, questionnaires)</arm_group_label>
    <arm_group_label>Retrospective(biospecimens, vision assessment, questionnaires)</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Tissue, saliva&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Retrospective patients (those treated between 2008 and 2018) identified by each site at the&#xD;
        start of the study period and prospective patients (those treated between 2018 and 2023)&#xD;
        identified at the time of diagnosis by each site during the study period with unilateral or&#xD;
        bilateral intraocular retinoblastoma&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        -  Unilateral or bilateral intraocular retinoblastoma&#xD;
&#xD;
          -  Diagnosis between the ages of 0 - 17.99 years&#xD;
&#xD;
          -  Diagnosis on or after January 1, 2008&#xD;
&#xD;
          -  No exclusions based on primary or secondary treatment modalities&#xD;
&#xD;
          -  Retrospective group patients must be ≥ 6 months post end of treatment at study entry&#xD;
&#xD;
               -  For those already at this timepoint, they are now eligible&#xD;
&#xD;
               -  For those in treatment, or otherwise not yet at this timepoint, they are eligible&#xD;
                  once at they are ≥ 6 months post end of treatment&#xD;
&#xD;
               -  Prospective group patients must not have begun treatment&#xD;
&#xD;
          -  Patients with diminished capacity will not be enrolled.&#xD;
&#xD;
          -  Language: Patients must be able to communicate in English, French, or Spanish&#xD;
&#xD;
          -  Sibling Cohort: One sibling, not affected by retinoblastoma will be enrolled,&#xD;
             preference for the sibling closest in age to the RB patient.&#xD;
&#xD;
          -  Regulatory Requirements: All patients and/or their parents or legal guardians must&#xD;
             sign a written informed consent. All institutional, FDA, and NCI requirements for&#xD;
             human studies must be met.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Debra Friedman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vanderbilt-Ingram Service for Timely Access</last_name>
    <phone>800-811-8480</phone>
    <email>cip@vanderbilt.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Lurie Children's Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Newmark</last_name>
      <email>mnewmark@luriechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Joanna Weinstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Illinois, Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristen kitsch</last_name>
      <email>kitsc@uic.edu</email>
    </contact>
    <investigator>
      <last_name>Mary Lou Schmidt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesoa</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kendra Pallin</last_name>
      <email>palli007@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Joseph Neglia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington School of Medicine at St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kara Sauerburger</last_name>
      <email>sauerburgerk@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Robert Hayashi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Pfeiffer</last_name>
      <email>amanda.pfeiffer@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>Rajaram Nagarajan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Markham</last_name>
      <email>markhams@chop.edu</email>
    </contact>
    <investigator>
      <last_name>Amish Shah, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanderbilt-Ingram Service for Timely Access</last_name>
      <phone>800-811-8480</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theresa Honey</last_name>
      <email>TAHoney@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Anna Herzog, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Childeren's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Najeeba Ali</last_name>
      <email>nmali@texaschildrens.org</email>
    </contact>
    <investigator>
      <last_name>Murali Chintagumpala, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Veronica Seher</last_name>
      <email>vseher@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>Cindy Schwartz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Hosptial for Sick Children</name>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roxanna Noronha</last_name>
      <email>roxanna.noronha@sickkids.ca</email>
    </contact>
    <investigator>
      <last_name>Helen Dimaras, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 15, 2019</study_first_submitted>
  <study_first_submitted_qc>April 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2019</study_first_posted>
  <last_update_submitted>April 19, 2021</last_update_submitted>
  <last_update_submitted_qc>April 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt-Ingram Cancer Center</investigator_affiliation>
    <investigator_full_name>Debra Friedman</investigator_full_name>
    <investigator_title>Sponsor Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinoblastoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

